MR feasibility tier: A — Published pQTL-MR estimates exist for this protein (retrieved below - not computed here).
| Outcome | beta | se | p | method | nSNP | cis/trans | coloc |
|---|---|---|---|---|---|---|---|
| Age at menopause | 0.0887 | 0.0222 | 6.33e-05 | Wald ratio | 1 | cis | NA |
| Birth weight | 0.0143 | 0.0041 | 4.89e-04 | Wald ratio | 1 | cis | NA |
| Fractured bone site(s): Ankle | -0.0732 | 0.0244 | 0.00274 | Wald ratio | 1 | cis | NA |
| Alcohol intake frequency | 0.0117 | 0.00393 | 0.00295 | Wald ratio | 1 | cis | NA |
| Birth length | 0.0311 | 0.0109 | 0.00414 | Wald ratio | 1 | cis | NA |
| Hearing difficulty or problems: Yes | -0.0119 | 0.00465 | 0.0102 | Wald ratio | 1 | cis | NA |
| Heel bone mineral density (BMD) T-score automated | 0.00863 | 0.00344 | 0.0122 | Wald ratio | 1 | cis | NA |
| Diagnoses - main ICD10: R10 Abdominal and pelvic pain | 0.0312 | 0.0124 | 0.0123 | Wald ratio | 1 | cis | NA |
| Non-cancer illness code self-reported: osteoarthritis | -0.0223 | 0.0091 | 0.0142 | Wald ratio | 1 | cis | NA |
| Neo-neuroticism | -0.248 | 0.105 | 0.0183 | Wald ratio | 1 | cis | NA |
| Neo-agreeableness | 0.152 | 0.068 | 0.0254 | Wald ratio | 1 | cis | NA |
| Mean cell haemoglobin | 0.0224 | 0.011 | 0.0413 | Wald ratio | 1 | cis | NA |
| …and 91 more outcomes (see JSON) |
No prot-* pQTL GWAS dataset found for this protein (matched by UniProt accession and symbol).
96 association rows across 56 traits (90 genome-wide significant rows). Associations are loci, not causal claims; the mapped gene at a locus is not necessarily the effector gene.
| Trait | best p | lead SNP | n assoc | study | MR status |
|---|---|---|---|---|---|
| Circulating LY75 levels | 3e-4883 | rs72957586 | 1 | GCST90860205 | no MR -> candidate analysis |
| Secretory phospholipase A2 receptor levels | 1e-619 | rs3749117 | 2 | GCST90249610 | no MR -> candidate analysis |
| Secretory phospholipase A2 receptor levels (PLA2R1.10916.44. | 6e-500 | rs3749117 | 2 | GCST90242737 | no MR -> candidate analysis |
| Bone mineral density mean | 1e-300 | rs147869749 | 1 | GCST90321120 | no MR -> candidate analysis |
| Serum levels of protein PLA2R1 | 1e-287 | rs55668231 | 1 | GCST90086499 | no MR -> candidate analysis |
| Circulating ITGB6 levels | 4e-253 | rs559273359 | 1 | GCST90860250 | no MR -> candidate analysis |
| Blood protein levels | 3e-158 | rs4665141 | 1 | GCST006585 | no MR -> candidate analysis |
| Lymphocyte antigen 75 levels | 8e-110 | rs116366652 | 1 | GCST90248352 | no MR -> candidate analysis |
| Membranous nephropathy | 5e-103 | rs17831251 | 4 | GCST010004 | no MR -> candidate analysis |
| MRC1 protein levels | 6e-99 | rs35771982 | 1 | GCST90469939 | no MR -> candidate analysis |
| LY75 protein levels | 4e-96 | rs147869749 | 27 | GCST90469822 | no MR -> candidate analysis |
| Circulating PLAU levels (id: OID00481_OID21124) | 1e-57 | rs3806603 | 1 | GCST90859841 | no MR -> candidate analysis |
| …and 44 more traits (see JSON) |
Top diseases by Open Targets association (of 394 total). Associations are loci, not causal claims. The causal-status column is a four-state triage per pair: established (curated) = a curated clinical assertion exists (ClinGen/G2P/GEL/Orphanet/ClinVar — any validity level, MR adds little); exploratory rare-variant signal = ExWAS burden evidence without curation — a candidate NEW gene-disease relationship; common-variant locus = GWAS signal, classic pQTL-MR territory; multi-layer = burden+GWAS together, an allelic-series candidate (the strongest causal setup). Burden estimand is carrier-vs-noncarrier, not per-SD MR.
| Disease | genetic assoc. | burden (ExWAS) | causal status | MR status |
|---|---|---|---|---|
| membranous glomerulonephritis | 0.87 | — | common-variant locus | no MR -> candidate analysis |
| hypertensive disorder | 0.691 | — | common-variant locus | no MR -> candidate analysis |
| clonal hematopoiesis | 0.495 | — | common-variant locus | no MR -> candidate analysis |
| response to COVID-19 vaccine | 0.453 | — | common-variant locus | no MR -> candidate analysis |
| hemorrhoid | 0.424 | — | common-variant locus | no MR -> candidate analysis |
| urolithiasis | 0.419 | — | common-variant locus | no MR -> candidate analysis |
| gastrointestinal disease | 0.419 | — | common-variant locus | no MR -> candidate analysis |
| alcohol drinking | 0.419 | — | common-variant locus | no MR -> candidate analysis |
| smoking initiation | 0.417 | — | common-variant locus | no MR -> candidate analysis |
| spondylolisthesis | 0.337 | — | common-variant locus | no MR -> candidate analysis |
| oropharynx cancer | 0.307 | — | common-variant locus | no MR -> candidate analysis |
| kidney disorder | 0.278 | — | established (curated) | no MR -> candidate analysis |
| substance abuse | 0.286 | — | common-variant locus | no MR -> candidate analysis |
| Chronic Obstructive Asthma | 0.228 | — | common-variant locus | no MR -> candidate analysis |
| adolescent idiopathic scoliosis | 0.104 | — | common-variant locus | no MR -> candidate analysis |
Of the 15 rows above, 15 have no MR estimate in this resource. Across all retrieved diseases for this gene: 0 exploratory rare-variant signal(s), 0 multi-layer (allelic-series candidate) pair(s). Final triage still belongs to a statistical geneticist.
| Layer | Result |
|---|---|
| ChEMBL druggability | 0 known modulators (Secretory phospholipase A2 receptor) |
| gnomAD constraint | pLI=9.4e-43, LOEUF=0.92 — LoF-tolerant |
| GWAS Catalog | 184 unique SNPs / 416 rows |
| ClinVar | 248 records; 0 pathogenic in sample of 30 |
| PharmGKB/ClinPGx | no annotations |
phenome — Top 30 of 394 associated diseases by overall score. genetic_association aggregates GWAS common-variant AND rare-variant evidence. These are ASSOCIATIONS (loci), not causal claims.chembl — ChEMBL target matched by text search on ‘PLA2R1’ and resolved to ‘Secretory phospholipase A2 receptor’ — confirm this is the intended target.clinvar — Pathogenic count is over the 30 record(s) retrieved, NOT over all 248 ClinVar records for this gene; it is a sample, not a rate.pharmgkb — No PharmGKB/ClinPGx clinical annotations (gene may not be a pharmacogene).gwas_traits — Top 20 of 56 traits by best p-value, aggregated from 96 association rows. These are GWAS ASSOCIATIONS (loci), not causal claims; mapped genes at a locus are not necessarily the effector gene.uniprot: https://www.uniprot.org/uniprotkb/Q13018 — UniProt release 2026_02 (10-June-2026)mr_outcomes: https://epigraphdb.org/pqtl/ — EpiGraphDB pQTL MR (Zheng et al., Nat Genet 2020) — pre-computed two-sample MR; retrieved, not computed by this agent; EpiGraphDB build 1.0, pQTL dataset v3.0phenome: https://platform.opentargets.org/target/ENSG00000153246/associations — Open Targets data release 26.06chembl: https://www.ebi.ac.uk/chembl/target_report_card/CHEMBL3713395/ — ChEMBL_37 (released 2026-05-01)gnomad: https://gnomad.broadinstitute.org/gene/PLA2R1 — gnomAD constraint via GraphQL API (reference genome GRCh38)gwas: https://www.ebi.ac.uk/gwas/genes/PLA2R1 — GWAS Catalog REST (live; release not exposed by this endpoint)clinvar: https://www.ncbi.nlm.nih.gov/clinvar/?term=PLA2R1%5Bgene%5D — ClinVar build Build260809-1055.1gwas_traits: https://www.ebi.ac.uk/gwas/genes/PLA2R1 — GWAS Catalog search API (live; release not exposed)